

NOVEMBER 2025 PBAC MEETING – CONSIDERATION OF THE REPORT OF THE  
DRUG UTILISATION SUB-COMMITTEE

## **PBAC CONSIDERATION OF THE REPORT OF THE DRUG UTILISATION SUB-COMMITTEE**

The PBAC noted reports with associated stakeholder responses from the October 2025 Drug Utilisation Sub-Committee (DUSC) meeting, which were provided in items 10.03, 10.04, and 10.05 of the PBAC Agenda. DUSC minutes relating to these items were provided to the PBAC. The outcomes of the DUSC consideration of these items are available in the [October 2025 DUSC outcome statement](#).

### **MEDICINES FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)**

#### *Outcome*

The PBAC noted the increase in the number of first-line incident and prevalent patients treated since the third quarter (Q3) of 2023, and that the number of second-line incident and prevalent patients treated has remained constant over the analysis period.

The PBAC noted the emerging evidence in relation to venetoclax retreatment (second-line) following fixed-dose venetoclax use in the first-line. However, the PBAC did not consider that the existing evidence was sufficient to alter the current venetoclax restrictions to allow for retreatment with venetoclax in the second-line.

The PBAC considered that, overall, patients were achieving a durable response and the use of treatments for CLL or SLL are in line with expectations and that no restriction changes are required.

### **DARATUMUMAB FOR NEWLY DIAGNOSED AMYLOID LIGHT-CHAIN AMYLOIDOSIS**

#### *Outcome*

The PBAC noted in 2024, 443 patients were supplied 4,881 prescriptions for the treatment of AL amyloidosis. The PBAC noted median age of patients initiating treatment with daratumumab for the treatment of AL amyloidosis was 70 years.

### **ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR (ELX/TEZ/IVA) FOR CYSTIC FIBROSIS**

#### *Outcome*

The PBAC noted that in 2024, 3,126 patients were supplied 30,208 prescriptions of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including 307 initiating patients. There were 27,089 prescriptions of the combination medicine ELX/TEZ/IVA supplied to 2,890 patients, including 209 initiating patients.

The PBAC noted that there was very rapid switching from other therapies to ELX/TEZ/IVA. The PBAC considered patients may be supplied PBS therapy of ELX/TEZ/IVA for longer than anticipated.

The PBAC commented on the consumer input to the review, noting how transformative therapy with CFTR modulators has been for these patients.